Patents by Inventor Angelo Ceci

Angelo Ceci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Publication number: 20210393644
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 23, 2021
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
    Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY
    Publication number: 20210069185
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Inventors: Angelo Ceci, Marcus Schindler
  • Use of Flibanserin in the treatment of obesity
    Patent number: 10874668
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: December 29, 2020
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Imidazopyridine derivatives and the use thereof as medicament
    Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
    Publication number: 20200121691
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
    Publication number: 20200123140
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament
    Publication number: 20200123141
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY
    Publication number: 20190282566
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: June 3, 2019
    Publication date: September 19, 2019
    Inventors: Angelo Ceci, Marcus Schindler
  • Use of flibanserin in the treatment of obesity
    Patent number: 10335407
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 2, 2019
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Imidazopyridine derivatives and the use thereof as medicament
    Publication number: 20190175605
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Georg DAHMANN, Cornelia DORNER-CIOSSEK, Lothar KUSSMAUL, Roland PFAU, Dieter WIEDENMAYER
  • Flibanserin for the treatment of urinary incontinence and related diseases
    Patent number: 10004731
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 26, 2018
    Inventors: Ramiro Castro, Angelo Ceci
  • Flibanserin for the Treatment of Urinary Incontinence and Related Diseases
    Publication number: 20180071282
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 15, 2018
    Inventors: Ramiro Castro, Angelo Ceci
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20180015084
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 18, 2018
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Flibanserin for the treatment of urinary incontinence and related diseases
    Patent number: 9763936
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 19, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Ramiro Castro, Angelo Ceci
  • Use of flibanserin in the treatment of obesity
    Patent number: 9730927
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 15, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20160136161
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 19, 2016
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Flibanserin for the Treatment of Urinary Incontinence and Related Diseases
    Publication number: 20160051545
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 25, 2016
    Inventors: Ramiro Castro, Angelo Ceci